Overview

A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

Status:
Recruiting

Trial end date:
2025-06-01

Target enrollment:

Participant gender:

Summary

This study will be conducted as a randomized, double-blind, placebo-controlled, multi-center Phase 3 study. Approximately 300 subjects with newly diagnosed glioblastoma who meet all eligibility criteria will be enrolled.

Phase:

Phase 3

Details

Lead Sponsor:

Denovo Biopharma LLC

Treatments:

Dacarbazine
Temozolomide